Skip to main content
    M

    Milestone Pharmaceuticals Inc (MIST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.79
    +0.01 (+0.84%)

    Market Cap: $95.34M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(20/30)
    Avg Surprise
    +3.04%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.23 - $-0.20
    5 analysts
    EPS Revisions
    2
    0
    7d
    2
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.21-1.0%
    60d ago$-0.21-1.0%
    30d ago$-0.21-1.0%
    7d ago$-0.210.0%
    Current$-0.21
    Revenue Consensus
    $1M
    Range$800000 - $2M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.62
    Range$-0.68 - $-0.55
    5 analysts
    Revenue Consensus
    $-35775140
    Range$-36803280 - $-33603280
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.62---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 12
    		$-0.21$-0.18-16.67%Miss-5.0%
    Mar 26
    Reported May 13
    		$-0.20$0.19-205.26%Miss+35.5%
    Dec 25
    Reported Mar 20
    		$-0.15$-0.16+6.25%Beat+21.1%
    Sep 25
    Reported Nov 12
    		$-0.12$-0.17+29.41%Beat+14.3%
    Jun 25
    Reported Aug 12
    		$-0.20$-0.18-11.11%Miss-42.9%
    Mar 25
    Reported May 14
    		$-0.31$-0.19-63.16%Miss-47.6%
    Dec 24
    Reported Mar 13
    		$-0.19$-0.15-26.67%Miss+40.6%
    Sep 24
    Reported Nov 12
    		$-0.14$-0.18+22.22%Beat+60.0%
    Jun 24
    Reported Aug 8
    		$-0.14$-0.20+30.00%Beat+62.2%
    Mar 24
    Reported May 13
    		$-0.21$-0.27+22.22%Beat+40.0%
    Dec 23
    Reported Mar 21
    		$-0.32$-0.31-3.23%Miss-3.2%
    Sep 23
    Reported Nov 13
    		$-0.35$-0.39+10.26%Beat-2.9%
    Jun 23
    Reported Aug 10
    		$-0.37$-0.39+5.13%Beat+5.1%
    Mar 23
    Reported May 11
    		$-0.35$-0.39+10.26%Beat-6.1%
    Dec 22
    Reported Mar 29
    		$-0.31$-0.33+6.06%Beat+22.5%
    Sep 22
    Reported Nov 10
    		$-0.34$-0.41+17.07%Beat+0.0%
    Jun 22
    Reported Aug 10
    		$-0.39$-0.37-5.41%Miss-2050.0%
    Mar 22
    Reported May 12
    		$-0.33$-0.38+13.16%Beat-10.0%
    Dec 21
    Reported Mar 24
    		$-0.40$-0.36-11.11%Miss-207.7%
    Sep 21
    Reported Nov 12
    		$-0.34$-0.35+2.86%Beat+15.0%
    Jun 21
    Reported Aug 11
    		$0.02N/A+105.71%Beat+103.8%
    Mar 21
    Reported May 17
    		$-0.30$-0.32+6.25%Beat+55.2%
    Dec 20
    Reported Mar 29
    		$-0.13N/A+68.29%Beat+79.4%
    Sep 20
    Reported Nov 13
    		$-0.40$-0.46+13.04%Beat+23.1%
    Jun 20
    Reported Aug 12
    		$-0.53$-0.43-23.26%Miss+5.4%
    Mar 20
    Reported May 14
    		$-0.67$-0.74+9.46%Beat-63.4%
    Dec 19
    Reported Mar 6
    		$-0.63$-0.51-23.53%Miss-
    Sep 19
    Reported Nov 13
    		$-0.52$-0.55+5.45%Beat-
    Jun 19
    Reported Aug 13
    		$-0.56$-0.56+0.00%Beat-
    Mar 19
    Reported May 9
    		$-0.41N/A+97.63%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.17EV/EBITDAN/A
    Price/FCF-1.60xFCF Yield-62.32%
    Profitability
    Profit Margin0.00%Operating Margin-4585.00%
    ROE-35523.00%ROIC-79.78%
    Financial Health
    Debt/Equity3.26xInterest Coverage-7.25x
    Current Ratio8.13xQuick Ratio7.92x
    Trading Statistics
    Beta1.01Avg Volume1.13M
    52-Week High$3.0652-Week Low$0.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.77
    SMA 20$0.81
    SMA 50$0.99
    SMA 200$1.45
    EMA 10$0.79
    EMA 20$0.83
    EMA 50$0.96
    EMA 200$1.32

    MACD

    Line: -0.06Signal: -0.07Hist: 0.01

    ADX

    ADX: 31.9+DI: 12.8-DI: 22.3

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down84.0
    PSAR$0.83

    Bollinger Bands

    Upper Band$0.93
    Lower Band$0.70
    %B Position2815%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    41.4

    Momentum Oscillators

    Stoch %K39.6
    Stoch %D37.6
    Williams %R-54.2
    ROC (10d)-2.6%
    Momentum-0.02
    CCI (20d)-47.1
    MFI (14d)48.5

    Volatility Measures

    ATR (14d)$0.06(7.6%)
    StdDev (20d)0.06
    Hist Vol67.2%(High)

    Volume Flow

    VWAP$0.78
    OBV-152.1M
    AD Line-72.3M
    CMF (20d)-0.080

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.9x
    VWMA (20d)$0.81

    Pivot Points

    R3$0.86
    R2$0.83
    R1$0.81
    Pivot Point$0.78
    S1$0.76
    S2$0.73
    S3$0.70

    Advanced Oscillators

    TSI-29.18
    Ultimate Osc54.4
    KST-225.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$559,000$238,000$1.55M$0$0$0$108,000$0$0$0$-868,002$0
    Cost of Revenue$32,000$14,000$34,000$0$0$0$567,000$0$0$0$532,000$0
    Gross Profit$527,000$224,000$1.55M$0$0$0$-567,000$0$0$0$-1,400,002$0
    Operating Expenses$26.16M$23.89M$18.80M$11.83M$12.53M$20.52M$12.35M$9.62M$9.66M$10.48M$13.80M$15.36M
    R&D$3.51M$3.25M$5.52M$3.94M$3.67M$4.98M$3.94M$3.96M$2.81M$3.64M$5.45M$6.72M
    SG&A$22.65M$4.82M$5.08M$3.26M$8.86M$5.17M$4.00M$3.74M$5.05M$3.95M$3.37M$4.23M
    Operating Income$-25,630,000$-23,663,000$-17,257,000$-11,829,000$-12,531,000$-20,523,000$-12,348,000$-9,616,000$-9,662,000$-10,476,000$-13,800,000$-15,360,000
    Interest Income$1.74M$1.73M$833,000$874,000$516,000$697,000$904,000$1.08M$1.19M$994,000$1.05M$1.12M
    Interest Expense$4.72M$4.13M$985,000$967,000$951,000$935,000$919,000$903,000$887,000$872,000$860,000$841,000
    Income Before Tax$-28,614,000$-26,066,000$-17,409,000$-11,922,000$-12,966,000$-20,761,000$-12,363,000$-9,439,000$-9,363,000$-10,354,000$-13,611,000$-15,081,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-28,614,000$-26,066,000$-17,409,000$-11,922,000$-12,966,000$-20,761,000$-12,363,000$-9,439,000$-9,363,000$-10,354,000$-13,611,000$-15,081,000
    EBITDA$-25,455,000$-23,490,000$-17,108,000$-11,695,000$-12,397,000$-20,394,000$-12,225,000$-9,496,000$-9,545,000$-10,361,000$-13,690,000$-15,256,000
    EBIT$-25,630,000$-23,663,000$-17,257,000$-11,829,000$-12,531,000$-20,523,000$-12,348,000$-9,616,000$-9,662,000$-10,476,000$-13,800,000$-15,360,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MIST

    News

    Milestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial Fibrillation

    Milestone Pharmaceuticals announced that the first European patient has been enrolled in its Phase 3 Etripamil trial for atrial fibrillation. The company (MIST) made this announcement on Friday, October 9, 2026...

    Yahoo Finance•10/10/26•Bullish

    Milestone enrolls first European patient in AFib-RVR trial By Investing.com

    Milestone Pharmaceuticals Inc. has enrolled the first European patient in its ReVeRA-301 Phase 3 trial, which is evaluating etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate...

    Investing.com Canada•10/9/26•Bullish

    A trial of a nasal spray for fast, irregular heartbeats enrolls its first European patient.

    Milestone Pharmaceuticals has enrolled its first European patient in the Phase 3 ReVeRA-301 clinical trial for its etripamil nasal spray...

    Stock Titan•10/9/26•Bullish

    Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

    Milestone Pharmaceuticals announced the enrollment of the first European patient in its ReVeRA-301 Phase 3 clinical trial...

    The Manila Times•10/9/26•Bullish

    Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

    Milestone Pharmaceuticals announced the enrollment of the first European patient in its ReVeRA-301 Phase 3 clinical trial for etripamil nasal spray...

    The Manila Times•10/9/26•Bullish

    MIST Valuation and Fair Value

    P/E
    -1.2x
    P/FCF
    -1.6x
    P/B
    5.4x
    See GNG's fair value

    MIST Profitability: Margins, ROIC and FCF

    Operating margin
    -4585.0%
    Net margin
    0.0%
    ROIC
    -79.8%
    ROE
    -35523.0%
    FCF margin
    -2631.1%
    FCF yield
    -62.3%

    MIST Competitors

    CompanyTicker
    ImmuCell CorporationICCC
    Rani Therapeutics Holdings IncRANI
    Coya Therapeutics, Inc. Common StockCOYA
    Pmv Pharmaceuticals IncPMVP
    PolyPidPYPD
    Anixa Biosciences IncANIX
    The Joint CorpJYNT
    Insight Molecular Diagnostics Inc.IMDX

    Sector: Healthcare

    MIST Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    5
    Hold
    1
    Sell
    0
    Strong Sell
    0

    MIST Bull Case vs Bear Case

    Bull case

    • 85.7% of MIST's analyst ratings are Buy or Strong Buy.

    Bear case

    • MIST beat EPS estimates in 37.5% of its last 8 reported quarters.
    • MIST's quarterly revenue changed -100.0% year over year.
    • MIST has a debt-to-equity ratio of 3.3x.

    MIST Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -33.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.21
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 2 down

    Frequently Asked Questions About MIST

    Does MIST pay dividends?

    Milestone Pharmaceuticals Inc (MIST) does not currently pay a regular dividend.

    What is MIST's market cap?

    Milestone Pharmaceuticals Inc (MIST) has a market capitalization of $95.34M with a current stock price of $0.79.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In